- Home
- HRZN vs OTLK Comparison
HRZN vs OTLK Comparison
Compare HRZN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRZN | OTLK |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.1M | 249.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HRZN | OTLK |
|---|---|---|
| Price | $4.41 | $1.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $6.50 | $2.50 |
| AVG Volume (30 Days) | 869.5K | ★ 22.3M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 33.85% | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | $12.25 | $1,430.98 |
| Revenue Next Year | $22.53 | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $0.16 |
| 52 Week High | $8.46 | $3.39 |
Technical Indicators
Market Signals| Indicator | HRZN | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 75.78 |
| Support Level | $3.96 | $1.60 |
| Resistance Level | $4.73 | $2.09 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 52.07 | 88.79 |
Price Performance
Historical ComparisonAbout HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.